〇Daiki Tatematsu¹, Shingo Iwami¹ (1. Nagoya University)

〇RUIMING LI¹, Satoru Sugimoto¹, Eiryo Kawakami¹ (1. Institute of Physical and Chemical Research)

〇Eriko Hasumi¹, Chen Yein^1,3, Sumie Miyamoto², Katsuhito Fujiu^1,2 (1. The university of Tokyo Hospital, 2. The university of Tokyo , 3. SIMPLEX QUANTUM co.)

〇Ryouichi Chatani¹, Shotaro Sonoike¹, Mariko Nio¹, Masayuki Kaneko¹, Isao Sano², Hiroki Kato³, Hiroko Otaki⁴, Yoichi Nakamoto³, Kunihiko Kido⁴, Naoki Fukazawa¹ (1. Clinical Development Division, Chugai Pharmaceutical Co., Ltd., 2. Digital Transformation Unit, Chugai Pharmaceutical Co., Ltd., 3. Industrial Digital Business Unit, Hitachi, Ltd., 4. Research & Development Group, Hitachi, Ltd.)

〇Takanori Kawabata^1,2, Kohtaro Fujihashi^3,4,5,6,7, Rika Nakahashi^3,4,5, Tomoyuki Yamanoue^3,4, Machita Tomonori^3,4, Taku tsuzuki^8,4, Tsuyoshi Tatsukawa^8,4, Eiryo Kawakami^1,9,10 (1. Department of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, 2. National Cerebral and Cardiovascular Center, 3. Department of Human Vaccinology, Chiba University Hospital, 4. Chiba University Snergy Institute for Futuristic Mucosal Vaccine Research and Development, 5. Division of Infectious Disease Vaccine Research and Development, Research Institute of Disaster Medicine, Chiba University, 6. Division of Mucosal Vaccine, International Vaccine Design Center, Institute of Medical Science,The University of Tokyo, 7. Department of Pediatric Dentistry, School of Dentistry, The University of Alabama at Birmingham, 8. Epistra Inc., 9. Advanced Data Science Project (ADSP), RIKEN Information R&D and Strategy Headquarters, RIKEN, 10. Institute for Advanced Academic Research (IAAR), Chiba University)

〇Yohei Kondo¹ (1. Nagoya University)

Osamu Saisho¹, 〇Akihiro Shiozawa², Shingo Tsukada¹, Takuji Oba² (1. Nippon Telegraph and Telephone, 2. NTT DATA Mathematical Systems Inc.)

〇Rie Shiokawa¹, Miho Li¹, Kimio Terao¹, Junichiro Iwasawa², Yuta Tokuoka², Kazue Mizuno², Yohei Sugawara², Keita Oda² (1. Chugai Pharmaceutical Co., Ltd., 2. Preferred Networks, Inc.)

〇Xuyang ZHAO^1,2, Qibin Zhao³, Toshihisa Tanaka⁴ (1. RIKEN Information R&D and Strategy Headquarters, 2. Chiba University, 3. RIKEN Center for Advanced Intelligence Project, 4. Tokyo University of Agriculture and Technology)

〇Ryosaku Ota¹, Naoki Honda¹ (1. Nagoya University)

〇Shinichi Tsuchiwata¹ (1. Pfizer R&D Japan)

〇Yuto Shimazaki^1,2, Masako Yamazaki¹, Teruto Hashiguchi³, Osamu Kumano⁴, Masahiro Ieko⁵, Yuta Fujimori⁶, Masatoshi Wakui⁷, Tetsuo Ishikawa^1,2,7, Eiryo Kawakami^1,2 (1. Chiba University , 2. RIKEN, 3. Kagoshima University , 4. National Institute of Advanced Industrial Science and Technology, 5. Sapporo University of Health Sciences, 6. Keio University Hospital, 7. Keio University)

〇Sho Oshima¹, Yuji Okamoto¹, Taisei Tosaki^1,2, Yasushi Okuno^1,2 (1. Kyoto university, 2. Riken Center for Computational Science)

〇Yohko Konno¹ (1. Hokkaido University)

〇Junna Oba¹, Tetsuo Ishikawa¹ (1. Keio University School of Medicine )

Keita Nakao^3,1, 〇Yuichiro Yada¹, Honda Naoki^1,2,3 (1. Nagoya University Graduate School of Medicine, 2. Center for One Medicine Innovative Translational Research (COMIT), Nagoya University, 3. Hiroshima University)

〇Naotoshi Nakamura¹ (1. Yokohama City University)

〇Hisahiro Ikari¹, Seiya Kawano³, Koichiro Yoshino³, Tokiko Watanabe², Shunsuke Tagami⁴, Yasuo Yoshioka², Eiryo Kawakami¹ (1. Chiba University, 2. Research Institute for Microbial Diseases, Osaka University, 3. RIKEN Information R&D and Strategy Headquarters., 4. RIKEN Center for Biosystems Dynamics Research)

〇Kyogo Wagatsuma¹, Satoru Sugimoto¹, Tetsuo Ishikawa¹, Megumi Oya¹, Eiryo Kawakami¹ (1. RIKEN)